Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Fate Therapeutics appointed Jamie Harrell as Senior Vice President, Market Development & Commercial Operations, effective October 12, 2026, in a newly created role. Harrell brings 25+ years of commercial experience, including launching lupus nephritis therapy voclosporin at Aurinia and work on blockbusters Remicade, Lovenox, and Synagis.
Key figures
- Years experience
- more than 25 years
- Products commercialized
- more than 25 products
- Prior blockbusters annual us sales
- over $1 billion each (Lovenox, Remicade, Synagis)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.